The Circular Life of Human CD38: From Basic Science to Clinics and Back

Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature

(2020) Ramón Lecumberri et al.   AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS

CD38: Modulating Histone Methyltransferase EZH2 Activity in SLE

(2020) Paramita Chakraborty et al.   TRENDS IN IMMUNOLOGY

The CD38/NAD/SIRTUIN1/EZH2 Axis Mitigates Cytotoxic CD8 T Cell Function and Identifies Patients with SLE Prone to Infections

(2020) Eri Katsuyama et al.   Cell Reports

CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults

(2020) Francesco Lanza et al.   Cancers

Targeting of CD38 by the tumor suppressor miR-26a serves as a novel potential therapeutic agent in multiple myeloma

(2020) Yi Hu et al.   CANCER RESEARCH

Daratumumab inhibits acute myeloid leukaemia metabolic capacity by blocking mitochondrial transfer from mesenchymal stromal cells

(2020) Jayna J Mistry et al.   HAEMATOLOGICA

Daratumumab as successful initial therapy for AL amyloidosis with nerve involvement

(2020) Shweta Deshpande et al.   LEUKEMIA & LYMPHOMA

Daratumumab for quick and sustained remission in post-transplant relapsed/refractory acute lymphoblastic leukemia

(2020) Yongping Zhang et al.   LEUKEMIA RESEARCH

Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade

(2020) Rui Yang et al.   Journal for ImmunoTherapy of Cancer

Dysregulation of Signaling Pathways Due to Differentially Expressed Genes From the B-Cell Transcriptomes of Systemic Lupus Erythematosus Patients – A Bioinformatics Approach

(2020) S. Udhaya Kumar et al.   Frontiers in Bioengineering and Biotechnology

CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond

(2020) Dario Roccatello et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses

(2020) Alak Manna et al.   Blood Advances

Solitary Plasmacytoma: a Review of Diagnosis and Management

(2019) Andrew Pham et al.   Current Hematologic Malignancy Reports

Mechanism of action of a new anti-CD38 antibody: enhancing myeloma immunotherapy

(2019) Fabio Malavasi et al.   CLINICAL CANCER RESEARCH

The Mechanism Of Action Of The Anti-CD38 Monoclonal Antibody Isatuximab In Multiple Myelmoa

(2019) Laura Moreno et al.   CLINICAL CANCER RESEARCH

Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia

(2019) Alak Manna et al.   CLINICAL CANCER RESEARCH

A reduction in B, T, and NK cells expressing CD38 by TAK-079 inhibits the induction and progression of collagen-induced arthritis in cynomolgus monkeys

(2019) Wouter Korver et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy

(2019) Alberto L. Horenstein et al.   Frontiers in Immunology

The Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases

(2019) Kelly A. Hogan et al.   Frontiers in Immunology

Post‐allogeneic transplant Evans syndrome successfully treated with daratumumab

(2019) Richard Blennerhassett et al.   BRITISH JOURNAL OF HAEMATOLOGY

Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia

(2019) Yishai Ofran et al.   LEUKEMIA

In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab

(2019) Djordje Atanackovic et al.   LEUKEMIA

Successful treatment with daratumumab for post‐HSCT refractory hemolytic anemia

(2019) Ehud Even‐Or et al.   PEDIATRIC BLOOD & CANCER

Editorial: Immunotherapy in Multiple Myeloma

(2019) Nicola Giuliani et al.   Frontiers in Immunology

The transferrin receptor CD71 regulates type II CD38, revealing tight topological compartmentalization of intracellular cyclic ADP-ribose production

(2019) Qi Wen Deng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Resolving the topological enigma in Ca2+-signaling by cyclic ADP-ribose and NAADP

(2019) Hon Cheung Lee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab

(2019) Thomas G. Martin et al.   Cells

Daratumumab in combination with standard treatment for autoimmune hemolytic anemia in a pediatric patient

(2019) Laura Cooling et al.   TRANSFUSION

Immunomodulatory effects of CD38-targeting antibodies

(2018) Niels W.C.J. van de Donk   IMMUNOLOGY LETTERS

Canonical and non-canonical adenosinergic pathways

(2018) E. Ferretti et al.   IMMUNOLOGY LETTERS

A phylogenetic view of the leukocyte ectonucleotidases

(2018) Enza Ferrero et al.   IMMUNOLOGY LETTERS

Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia

(2018) Nathaniel J Buteyn et al.   INTERNATIONAL IMMUNOLOGY

Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors

(2018) Alberto L. Horenstein et al.   Frontiers in Pharmacology

Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+

(2018) F. Morandi et al.   OncoImmunology

Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells

(2018) Aneel Paulus et al.   BRITISH JOURNAL OF HAEMATOLOGY

Long-term response to daratumumab in a patient with advanced immunoglobulin light-chain (AL) amyloidosis with organ damage

(2018) Martina Canichella et al.   ANNALS OF HEMATOLOGY

Functional insights into nucleotide-metabolizing ectoenzymes expressed by bone marrow-resident cells in patients with multiple myeloma

(2018) A.L. Horenstein et al.   IMMUNOLOGY LETTERS

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

(2016) J. Krejcik et al.   BLOOD

The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia

(2016) Alba Matas-Céspedes et al.   CLINICAL CANCER RESEARCH

Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates With Progression of Human Myeloma

(2016) Alberto L Horenstein et al.   MOLECULAR MEDICINE

Targeting CD38 in Refractory Extranodal Natural Killer Cell–T-Cell Lymphoma

(2016) Parameswaran Hari et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD56brightCD16−NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+T Cell Proliferation

(2015) Fabio Morandi et al.   JOURNAL OF IMMUNOLOGY

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

(2015) Marije B Overdijk et al.   mAbs

A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation

(2015) Fabio Morandi et al.   Oncotarget

NAD+-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model

(2015) Alberto Horenstein et al.   Cells

Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche

(2014) Valeria Quarona et al.   Annals of the New York Academy of Sciences

Nucleotide signalling during inflammation

(2014) Marco Idzko et al.   NATURE

A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes

(2013) Alberto L Horenstein et al.   OncoImmunology

Tetrameric Interaction of the Ectoenzyme CD38 on the Cell Surface Enables Its Catalytic and Raft-Association Activities

(2012) Miki Hara-Yokoyama et al.   STRUCTURE

Editorial: CD38 and retinoids: a step toward a cure

(2011) Fabio Malavasi   JOURNAL OF LEUKOCYTE BIOLOGY

CD38 as a Regulator of Cellular NAD: A Novel Potential Pharmacological Target for Metabolic Conditions

(2009) Eduardo Chini   CURRENT PHARMACEUTICAL DESIGN

Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology

(2008) Fabio Malavasi et al.   PHYSIOLOGICAL REVIEWS